Abstract
Men with high-risk localized prostate cancer exhibit high rates of post-surgical recurrence. In these patients, androgen deprivation therapy (ADT) is immunomodulatory, however increased infiltration of regulatory T cells (Tregs) may limit the antitumor immune effects of ADT. We designed a neoadjuvant clinical trial to test whether BMS-986218 – a next-generation non-fucosylated anti-CTLA-4 antibody engineered for enhanced antibody-dependent cellular cytotoxicity or phagocytosis (ADCC/P) – depletes intratumoral Tregs and augments the response to ADT. In this single-center, two-arm, open-label study, 24 men with high-risk localized prostate cancer were randomized to receive a single dose of ADT with or without two pre-operative doses of BMS-986218 (anti-CTLA4-NF) prior to radical prostatectomy. Treatment was well tolerated and feasible in the neoadjuvant setting. A secondary clinical outcome was the rate of disease recurrence, which was lower than predicted in both arms. Mechanistically, anti-CTLA4-NF reduced ADT-induced Treg accumulation through engagement of CD16a/FCGR3A on tumor macrophages, and depth of Treg depletion was quantitatively associated with clinical outcome. Increased intratumoral dendritic cell (DC) frequencies also associated with lack of recurrence, and pre-clinical data suggest ADCC/P-competent anti-CTLA-4 antibodies elicit activation and expansion of tumor DCs. Patients receiving anti-CTLA4-NF also exhibited phenotypic signatures of enhanced antitumor T cell priming. In total, this study provides the first-in-human evidence of Treg depletion by glycoengineered antibodies targeting CTLA-4 in humans and their potential in combination with ADT in prostate cancer patients with high-risk of recurrence.
Competing Interest Statement
C.G.D is a co-inventor on patents licensed from Johns Hopkins University to BMS and Janssen. He is currently a paid employee of JnJ Innovative Medicine. A.C. is founder, equity holder, consultant, and director of DarwinHealth Inc., which has licensed IP related to these algorithms from Columbia University. Columbia University is an equity holder in DarwinHealth Inc.
Clinical Trial
NCT04301414
Funding Statement
This research was supported by National Institutes of Health (NIH) grants 1P50CA58236-15 and P30CA006973, the Prostate Cancer Foundation Challenge Grant, TJ Martell Foundation funds, and CUMC institutional funds to C.G.D, the NCI Center for Cancer Systems Therapeutics (CaST) award U54CA274506, the NCI Outstanding Investigator award R35 CA197745, and the NIH Shared Instrumentation Grants S10 OD012351, S10 OD021764 and S10OD032433, to A.C., by a Prostate Cancer Foundation Young Investigator Award to M.D., by NIH grants UL1TR001873 and TL1TR001875, and institutional funds from Mayo Clinic to C.R.A., by NIH grant F30CA260765-01 to A.O., and by NIH/NIDDK grant T35DK093430 in support of A.L.E.W.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Columbia University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This research was supported by National Institutes of Health (NIH) grants 1P50CA58236-15 and P30CA006973, the Prostate Cancer Foundation Challenge Grant, TJ Martell Foundation funds, and CUMC institutional funds to C.G.D, the NCI’s Center for Cancer Systems Therapeutics (CaST) award U54CA274506, the NCI Outstanding Investigator award R35 CA197745, and the NIH Shared Instrumentation Grants S10 OD012351, S10 OD021764 and S10OD032433, to A.C., by a Prostate Cancer Foundation Young Investigator Award to M.D., by NIH grants UL1TR001873 and TL1TR001875, and institutional funds from Mayo Clinic to C.R.A., by NIH grant F30CA260765-01 to A.O., and by NIH/NIDDK grant T35DK093430 in support of A.L.E.W.
Conflicts of Interest: C.G.D is a co-inventor on patents licensed from Johns Hopkins University to BMS and Janssen. He is currently a paid employee of JnJ Innovative Medicine. A.C. is founder, equity holder, consultant, and director of DarwinHealth Inc., which has licensed IP related to these algorithms from Columbia University. Columbia University is an equity holder in DarwinHealth Inc.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
